The crisis of no new antibiotics-what is the way forward?

The Lancet Infectious Diseases

Volumn 12, Issue 3, 2012, Pages 249-253

  Piddock, Laura J V ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; NEW DRUG; VACCINE;

ADULTHOOD; ANTIBIOTIC RESISTANCE; CHILD; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG RESEARCH; HEALTH CARE PERSONNEL; HUMAN; INFECTION CONTROL; LICENSING; NOTE; PRIORITY JOURNAL; PROFIT; PUBLIC HEALTH PROBLEM; SURVIVAL; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; WORLD HEALTH ORGANIZATION;

ANTI-BACTERIAL AGENTS; DRUG AND NARCOTIC CONTROL; DRUG DISCOVERY; HUMANS; LICENSURE; RESEARCH;

EID: 84857195282     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70316-4     Document Type: Note

References (52)

1. Levy SB, Marshall B Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004, 10(12 suppl):S122-S129.
2. Innovative mechanisms for tackling antibacterial resistance. RS Policy document 14/08 2008, Royal Society, The Royal Society, London.
3. Spellberg B, Blaser M, Guidos RJ, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011, 52(suppl 5):S397-S428.
4. Cars O, Hedin A, Heddini A The global need for effective antibiotics-moving towards concerted action. Drug Resist Updat 2011, 14:68-69.
5. Wise R The urgent need for new antibacterial agents. J Antimicrob Chemother 2011, 66:1939-1940.
6. Carlet J, Collignon P, Goldmann D, et al. Society's failure to protect a precious resource: antibiotics. Lancet 2011, 378:369-371.
7. Hughes JM Preserving the lifesaving power of antimicrobial agents. JAMA 2011, 305:1027-1028.
8. Clatworthy AE, Pierson E, Hung DT Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 2007, 3:541-548.
9. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997, 337:441-446.
10. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
11. De Wals P, Robin E, Fortin E, Thibeault R, Ouakki M, Douville-Fradet M Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2008, 27:963-968.
12. Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010, 16:816-823.
13. Chan-Tompkins NH Multidrug-resistant gram-negative infections. Bringing back the old. Crit Care Nurs Q 2011, 34:87-100.
14. Gagliotti C, Balode A, Baquero F, et al. Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill 2011, 16. (published online March 17) PII:19819.
15. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
16. Sacks R, Greene L Impact of antibiotic resistance. BMJ 2011, 342:d3523.
17. Top 10 causes of death WHO, (accessed Nov 10, 2011). http://www.who.int/mediacentre/factsheets/fs310/en/.
18. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
19. Kuehn BM Proposals seek to reduce resistance, boost development of new antibiotics. JAMA 2011, 305:1845-1846.
20. Innovative Incentives for Effective Antibacterials. Stockholm, Sweden; Sept 17, 2009 Swedish Presidency of the European Union. http://www.se2009.eu/polopoly_fs/1.25861!menu/standard/file/Antibacterials5.pdf.
21. The Urgent Need Working-Regeneration of Antibacterial Drug Discovery and Development British Society for Antimicrobial Chemotherapy, (accessed Nov 10, 2011). http://www.bsac.org.uk/News/TUN.
22. Livermore DM Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011, 66:1941-1944.
23. Finch R Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. J Antimicrob Chemother 2011, 66:1945-1947.
24. White AR Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. J Antimicrob Chemother 2011, 66:1948-1953.
25. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007, 6:29-40.
26. Jeon B, Zhang Q Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide antibiotics by antisense inhibition of the CmeABC multidrug efflux transporter. J Antimicrob Chemother 2009, 63:946-948.
27. Lomovskaya O, Bostian KA Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem Pharmacol 2006, 71:910-918.
28. Piddock LJ, Garvey MI, Rahman MM, Gibbons S Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria. J Antimicrob Chemother 2010, 65:1215-1223.
29. Ricci V, Piddock LJ Exploiting the role of TolC in pathogenicity: identification of a bacteriophage for eradication of Salmonella serovars from poultry. Appl Environ Microbiol 2010, 76:1704-1706.
30. Fischetti VA Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 2008, 11:393-400.
31. Garvey MI, Rahman MM, Gibbons S, Piddock LJ Medicinal plant extracts with efflux inhibitory activity against Gram-negative bacteria. Int J Antimicrob Agents 2011, 37:145-151.
32. Lorenzi V, Muselli A, Bernardini AF, et al. Geraniol restores antibiotic activities against multidrug-resistant isolates from gram-negative species. Antimicrob Agents Chemother 2009, 53:2209-2211.
33. Bowser TE, Bartlett VJ, Grier MC, et al. Novel anti-infection agents: small-molecule inhibitors of bacterial transcription factors. Bioorg Med Chem Lett 2007, 17:5652-5655.
34. Barczak AK, Hung DT Productive steps toward an antimicrobial targeting virulence. Curr Opin Microbiol 2009, 12:490-496.
35. Baron C Antivirulence drugs to target bacterial secretion systems. Curr Opin Microbiol 2010, 13:100-105.
36. Chen G, Swem LR, Swem DL, et al. A strategy for antagonizing quorum sensing. Mol Cell 2011, 42:199-209.
37. Garrity-Ryan LK, Kim OK, Balada-Llasat JM, et al. Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model. Infect Immun 2010, 78:4683-4690.
38. Cottell JL, Webber MA, Coldham NG, et al. Complete sequence and molecular epidemiology of IncK epidemic plasmid encoding blaCTX-M-14. Emerg Infect Dis 2011, 17:645-652.
39. Fukuda D, Haines AS, Song Z, et al. A natural plasmid uniquely encodes two biosynthetic pathways creating a potent anti-MRSA antibiotic. PLoS One 2011, 6:e18031.
40. Laureti L, Song L, Huang S, et al. Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in Streptomyces ambofaciens. Proc Natl Acad Sci USA 2011, 108:6258-6263.
41. Williams KJ, Bax RP Challenges in developing new antibacterial drugs. Curr Opin Investig Drugs 2009, 10:7.
42. Okeke IN, Peeling RW, Goossens H, et al. Diagnostics as essential tools for containing antibacterial resistance. Drug Resist Updat 2011, 14:95-106.
43. Rice LB Rapid diagnostics and appropriate antibiotic use. Clin Infect Dis 2011, 52(suppl 4):S357-S360.
44. White AR The pharmaceutical approach to antibiotic policies 2005, Kluwer Academic/Plenum Publishers, New York.
45. Nathan C, Goldberg FM Outlook: the profit problem in antibiotic R&D. Nat Rev Drug Disc 2005, 4:887-891.
46. Projan SJ Why is Big Pharma getting out of antibacterial drug discovery?. Curr Opin Investig Drugs 2003, 6:427-430.
47. Morel C, Mossialos E Stoking the antibiotic pipeline. BMJ 2010, 340:c2115.
48. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009, 49:9.
49. Wilton P, Smith R, Coast J, Millar M Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy 2002, 7:7.
50. Recommendations for future collaboration between the U.S. and EU 2011 Transatlantic Taskforce on Antimicrobial Resistance, (accessed Nov 10, 2011). http://ecdc.europa.eu/en/activities/diseaseprogrammes/TATFAR/Pages/index.aspx.
51. The British Society for Antimicrobial Chemotherapy, (accessed Nov 10, 2011). http://www.antibioticaction.com/.
52. Chopra I, Schofield C, Everett M, et al. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis 2008, 8:133-139.